Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) ...

Leading allergy medical societies and patient advocacy groups highlight path forward to advance food allergy prevention, treatment, and managementWashington, DC, March 19, 2026 (GLOBE NEWSWIRE) -- The ...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EURneffy-t ...

Dupilumab yields larger improvements in lung function than several other biologics in patients with severe asthma.

CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Shoulder pain is one of the most common locations of chronic pain. It impacts quality of life and has the potential to become disabling for millions of ...

The approval is based on data from the SWIFT and ANCHOR phase 3 trials, which showed sustained efficacy with a twice-yearly dosing regimen for depemokimab. Each of the four trials met their primary or ...

Upstream Bio said a Phase 2 clinical trial for its respiratory-disease treatment met its primary endpoint in two dosing regimens, but that a third treatment group didn't see consistent improvements.

Use of single maintenance and reliever therapy (SMART) for moderate-to-severe asthma saved money by improving outcomes, according to a meta-analysis. While SMART is recommended by guidelines, ...

Arjun Mohan received funding from Verona Pharm LLC and Regeneron Pharm for Consulting Services (one time, relationship has ended). These services have no conflict with the article written here ...

*For decades, asthma treatment has focused on molecules called leukotrienes. These compounds cause inflammation, tighten airways, and make breathing harder. Drugs like Singulair were created to block ...